| 2022-07 |
Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S484. |
 |
| 2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer |
Annals of Oncology. 2022 Jul;33(Suppl. 6):S478. |
|
| 2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study |
Frontiers in Oncology. 2022 Jun 22;12:Article number 800842. |
|
| 2022-06-02 |
Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma |
Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536. |
|
| 2022-06 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin |
Journal of Hepato-Biliary-Pancreatic Sciences. 2022 Jun;54(5):607-612. |
|
| 2022-06 |
Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma |
Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120. |
|
| 2022-06 |
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements |
Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4009. |
|
| 2022-05-15 |
Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience |
American Journal of Cancer Research. 2022 May 15;12(5):2189-2202. |
|
| 2022-05 |
Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness |
Cancer Science. 2022 May;113(5):1601-1612. |
|
| 2022-04-18 |
The trinity: Interplay among cancer cells, fibroblasts, and immune cells in pancreatic cancer and implication of CD8(+) T cell-orientated therapy |
Biomedicines. 2022 Apr 18;10(4):Article number 926. |
|
| 2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan |
American Journal of Cancer Research. 2022 Apr 15;12(4):1884-1898. |
|
| 2022-04-11 |
Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment |
Journal of Experimental and Clinical Cancer Research. 2022 Apr 11;41:Article number 137. |
|
| 2022-04 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study |
British Journal of Cancer. 2022 Apr;126(7):1018-1026. |
|
| 2022-04 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials |
Journal for Immunotherapy of Cancer. 2022 Apr;10(4):Article number e004273. |
|
| 2022-02-24 |
Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway |
International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608. |
|
| 2022-02-16 |
Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma |
Cancers. 2022 Feb 16;14(4):Article number 1005. |
|
| 2022-02-15 |
Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1 |
American Journal of Cancer Research. 2022 Feb 15;12(2):713-728. |
|
| 2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 |
Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):378. |
|
| 2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma |
Journal of Clinical Oncology. 2022 Feb 01;40(4, Suppl.):550. |
|
| 2022-02 |
Incidence and survival variations of upper tract urothelial cancer in Taiwan (2001-2010) |
International Journal of Urology. 2022 Feb;29(2):121-127. |
|
| 2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr |
Lancet Oncology. 2022 Feb;23(2):234-247. |
|
| 2022-02 |
Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors |
Journal of Clinical Oncology. 2022 Feb;40(4, Suppl.):660. |
|
| 2022-01 |
Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation |
Journal of the Formosan Medical Association. 2022 Jan;121(1 Pt 1):170-180. |
|
| 2022-01 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study |
Gastric Cancer. 2022 Jan;25(1):207-217. |
|
| 2021-11-30 |
Survival outcomes of management in metastatic gastric adenocarcinoma patients |
Scientific Reports. 2021 Nov 30;11:Article number 23142. |
|
